SCHEMBL651474

SCHEMBL651474

O=CN(c1ncc(/C=C2\SC(=Nc3ccc4c(ccn4CCN4CCCC4)c3)NC2=O)s1)C1CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
MAPT P10636 10/20 0.34
RAB9A P51151 4/20 0.34
HCRTR1 O43613 1/20 0.34
POLB P06746 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
KMT2A Q03164 9/20 0.33
MEN1 O00255 8/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
PSMD14 O00487 1/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPK1 P28482 2/20 0.33
USP2 O75604 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
SAE1 Q9UBE0 1/20 0.33
UBA2 Q9UBT2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651037 0.99 NOS3 (0.36) NOS3NOS1NOS2MAPTRAB9A
SCHEMBL650363 0.95 HTR6 (0.33) NOS3NOS1NOS2MAPTRAB9A
SCHEMBL651596 0.94 NOS3 (0.34) NOS3NOS1NOS2MAPTRAB9A
SCHEMBL649047 0.86 MAPT (0.41) MAPTRAB9AHCRTR1POLBNPSR1
SCHEMBL651026 0.82 MAPT (0.34) NOS3NOS1NOS2MAPTRAB9A
SCHEMBL10176421 0.81 NOS3 (0.36) NOS3NOS1NOS2MAPTRAB9A
SCHEMBL10176423 0.81 NOS3 (0.38) NOS3NOS1NOS2MAPTRAB9A
SCHEMBL654530 0.79 NOS3 (0.33) NOS3NOS1NOS2
SCHEMBL650903 0.79 NOS3 (0.34) NOS3NOS1NOS2
SCHEMBL653944 0.77 MAPT (0.38) MAPTRAB9AHCRTR1POLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 NOS3 3616/4885NOS1 3844/4885NOS2 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.